Skip to main content
Premium Trial:

Request an Annual Quote

Pluristyx, Pancella, Implant Therapeutics Agree to Merge

NEW YORK — Pluristyx, Pancella, and Implant Therapeutics said on Thursday that they have agreed to merge into a single company providing induced pluripotent stem cell (iPSC)-related products and services.

Under the terms of the deal, which is contingent on shareholder approval, the new company will operate under the Pluristyx name, with Pancella becoming a wholly owned subsidiary of the new firm. Implant Therapeutics is a subsidiary of Pancella.

"This merger takes us one step farther in our journey to become the leading provider of iPSC and cell therapy solutions for research, diagnostic, and clinical applications," Benjamin Fryer, CEO of Seattle-based Pluristyx, said in a statement. "Together with the expertise and technology portfolio of Pancella, we can now provide a full suite of tools and provide the fastest path to gene-edited iPSC-based therapies."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.